ID

14769

Descripción

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe); ODM derived from: https://clinicaltrials.gov/show/NCT02269813

Link

https://clinicaltrials.gov/show/NCT02269813

Palabras clave

Versiones (1)
  1. 27/4/16 27/4/16 -
Subido en

27 de abril de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT02269813

Inglés

Eligibility Breast Cancer NCT02269813

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
women with histologically proven invasive stage 1 and 2 breast cancer
Descripción

Gender | Invasive breast carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0853879
hormone receptor positive according to local standards
Descripción

Hormone Receptor Positive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C1446409
her2 negative - i.e. ihc 0-1+, or fish or other ish non-amplified (locally assessed)
Descripción

Human epidermal growth factor 2 negative carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2316304
UMLS CUI [2]
C0021044
UMLS CUI [3]
C0162789
axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm or micro metastases i.e. >0.2-2mm)
Descripción

axillary lymph node Status | Macrometastasis | Neoplasm Micrometastasis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1279048
UMLS CUI [1,2]
C0449438
UMLS CUI [2]
C3829229
UMLS CUI [3]
C1513276
≥ 18 years of age at time of consent
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
Descripción

eligible Adjuvant Chemotherapy Hormone Therapy | Karnofsky Performance Status | Medical contraindication Hematological Disease Heart Diseases Liver diseases | Comorbidity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1548635
UMLS CUI [1,2]
C0085533
UMLS CUI [1,3]
C0279025
UMLS CUI [2]
C0206065
UMLS CUI [3,1]
C1301624
UMLS CUI [3,2]
C0018939
UMLS CUI [3,3]
C0018799
UMLS CUI [3,4]
C0023895
UMLS CUI [4]
C0009488
written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
≥4 involved axillary nodes
Descripción

Axillary lymph node group

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0729594
multi-centric disease with more than 2 clinically relevant lesions
Descripción

Multicentric Breast Carcinoma Lesion

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2986664
UMLS CUI [1,2]
C0221198
hr negative or her2 positive/amplified (locally assessed)
Descripción

Hormone Receptor Negative | HER2-positive carcinoma of breast

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0205160
UMLS CUI [2]
C1960398
previous diagnosis of malignancy unless disease free for 10 years
Descripción

Prior diagnosis Malignant Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332132
UMLS CUI [1,2]
C0006826
metastatic disease
Descripción

Neoplasm Metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027627
tumor sample shipped to agendia with ≤ 30% tumor cells or that fails qa or qc criteria
Descripción

Tumor tissue sample | quality assurance | quality control

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0475358
UMLS CUI [2]
C0178932
UMLS CUI [3]
C0034378
women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
Descripción

Gender | Adjuvant Chemotherapy Breast Carcinoma | Neoadjuvant Therapy Breast Carcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0085533
UMLS CUI [2,2]
C0678222
UMLS CUI [3,1]
C0600558
UMLS CUI [3,2]
C0678222
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT02269813

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Invasive breast carcinoma
Item
women with histologically proven invasive stage 1 and 2 breast cancer
boolean
C0079399 (UMLS CUI [1])
C0853879 (UMLS CUI [2])
Hormone Receptor Positive
Item
hormone receptor positive according to local standards
boolean
C0019929 (UMLS CUI [1,1])
C1446409 (UMLS CUI [1,2])
Human epidermal growth factor 2 negative carcinoma of breast | Immunohistochemistry | Fluorescent in Situ Hybridization
Item
her2 negative - i.e. ihc 0-1+, or fish or other ish non-amplified (locally assessed)
boolean
C2316304 (UMLS CUI [1])
C0021044 (UMLS CUI [2])
C0162789 (UMLS CUI [3])
axillary lymph node Status | Macrometastasis | Neoplasm Micrometastasis
Item
axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm or micro metastases i.e. >0.2-2mm)
boolean
C1279048 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C3829229 (UMLS CUI [2])
C1513276 (UMLS CUI [3])
Age
Item
≥ 18 years of age at time of consent
boolean
C0001779 (UMLS CUI [1])
eligible Adjuvant Chemotherapy Hormone Therapy | Karnofsky Performance Status | Medical contraindication Hematological Disease Heart Diseases Liver diseases | Comorbidity
Item
patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
boolean
C1548635 (UMLS CUI [1,1])
C0085533 (UMLS CUI [1,2])
C0279025 (UMLS CUI [1,3])
C0206065 (UMLS CUI [2])
C1301624 (UMLS CUI [3,1])
C0018939 (UMLS CUI [3,2])
C0018799 (UMLS CUI [3,3])
C0023895 (UMLS CUI [3,4])
C0009488 (UMLS CUI [4])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Axillary lymph node group
Item
≥4 involved axillary nodes
boolean
C0729594 (UMLS CUI [1])
Multicentric Breast Carcinoma Lesion
Item
multi-centric disease with more than 2 clinically relevant lesions
boolean
C2986664 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
Hormone Receptor Negative | HER2-positive carcinoma of breast
Item
hr negative or her2 positive/amplified (locally assessed)
boolean
C0019929 (UMLS CUI [1,1])
C0205160 (UMLS CUI [1,2])
C1960398 (UMLS CUI [2])
Prior diagnosis Malignant Neoplasms
Item
previous diagnosis of malignancy unless disease free for 10 years
boolean
C0332132 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Neoplasm Metastasis
Item
metastatic disease
boolean
C0027627 (UMLS CUI [1])
Tumor tissue sample | quality assurance | quality control
Item
tumor sample shipped to agendia with ≤ 30% tumor cells or that fails qa or qc criteria
boolean
C0475358 (UMLS CUI [1])
C0178932 (UMLS CUI [2])
C0034378 (UMLS CUI [3])
Gender | Adjuvant Chemotherapy Breast Carcinoma | Neoadjuvant Therapy Breast Carcinoma
Item
women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
boolean
C0079399 (UMLS CUI [1])
C0085533 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
C0600558 (UMLS CUI [3,1])
C0678222 (UMLS CUI [3,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial